Regional map of medicines
Brazil
297,138people on antiretroviral treatment (2013)
Mixedhealth insurance model
Antiretroviral medicines (2013)
| Medicine | Unit price (US$) | Cost per person per year (US$) | Patent in force | Data protection | Monopoly | Possible savings per person per year (US$) |
|---|---|---|---|---|---|---|
| Abacavir 300 mg | 0.31 | 226 | Yes | No | No | 55 |
| Atazanavir 300 mg | 2.8 | 1,022 | Yes | No | Yes | 791 |
| Etravirina 100 mg | 3.84 | 5,611 | Yes | No | Yes | 6,078 |
| Lopinavir Ritonavir 200mg - 50 mg | 0.47 | 689 | Yes | No | Yes | 320 |
| Raltegravir 400 mg | 7 | 5,111 | No | No | Yes | 3,359 |
| Emtricitabina Tenofovir 200mg - 300 mg | 0 | 0 | No | No | No | 0 |
| Maraviroc 300 mg | — | — | — | — | — | — |
| Emtricitabina-tenofovir-efavirenz 600 mg - 300 mg - 200 mg | — | — | Yes | — | — | — |
Epidemiological data
| Year | People on treatment | People without treatment | Treatment coverage |
|---|---|---|---|
| 2013 | 297,138 | — | — |
| 2018 | Prevalencia en 2018: 900.000 (todas las edades) | — | — |
| 2019 | Incidencia acumulada desde 1980 hasta 2018: 17.099 niños y 700.203 adultos | — | — |
Health coverage
- Insurance model
- Mixed (subsidized and contributive)
- Provision of antiretrovirals
- Free , provided by the Sistema Único de Saúde (SUS)
- Procurement of antiretrovirals
- Centralized by the SUS
The data were provided by RedLAM member organizations at the time; each table shows the year.